HK1220978A1 - N-[5-(氨基磺酰基)-4-甲基-1，3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物 - Google Patents
N-[5-(氨基磺酰基)-4-甲基-1，3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物 Download PDFInfo
- Publication number
- HK1220978A1 HK1220978A1 HK16109165.2A HK16109165A HK1220978A1 HK 1220978 A1 HK1220978 A1 HK 1220978A1 HK 16109165 A HK16109165 A HK 16109165A HK 1220978 A1 HK1220978 A1 HK 1220978A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methyl
- thiazol
- aminosulfonyl
- phenyl
- pyridinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11007823.5 | 2011-09-26 | ||
| EP11007823A EP2573086A1 (en) | 2011-09-26 | 2011-09-26 | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14108902.4A Addition HK1196018B (en) | 2011-09-26 | 2012-09-26 | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14108902.4A Division HK1196018B (en) | 2011-09-26 | 2012-09-26 | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1220978A1 true HK1220978A1 (zh) | 2017-05-19 |
Family
ID=46889067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16109165.2A HK1220978A1 (zh) | 2011-09-26 | 2014-09-02 | N-[5-(氨基磺酰基)-4-甲基-1，3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9340535B2 (enExample) |
| EP (3) | EP2573086A1 (enExample) |
| JP (2) | JP6161614B2 (enExample) |
| KR (4) | KR20170055565A (enExample) |
| CN (2) | CN103842359B (enExample) |
| AR (3) | AR088043A1 (enExample) |
| AU (2) | AU2012314536B2 (enExample) |
| BR (1) | BR112014003245B1 (enExample) |
| CA (1) | CA2791142C (enExample) |
| CL (1) | CL2014000149A1 (enExample) |
| DK (2) | DK2598501T3 (enExample) |
| ES (2) | ES2466221T3 (enExample) |
| HK (1) | HK1220978A1 (enExample) |
| HR (1) | HRP20140351T1 (enExample) |
| IL (2) | IL230152A (enExample) |
| IN (1) | IN2014DN01993A (enExample) |
| JO (2) | JO3037B1 (enExample) |
| MX (2) | MX371088B (enExample) |
| MY (2) | MY190878A (enExample) |
| PE (1) | PE20141148A1 (enExample) |
| PH (2) | PH12014500567A1 (enExample) |
| PL (2) | PL2602258T3 (enExample) |
| PT (1) | PT2598501E (enExample) |
| RU (2) | RU2620604C2 (enExample) |
| SG (1) | SG10201407430TA (enExample) |
| TW (2) | TWI567070B (enExample) |
| UA (2) | UA115317C2 (enExample) |
| WO (1) | WO2013045479A1 (enExample) |
| ZA (2) | ZA201401773B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2573086A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
| EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| GEP20207128B (en) * | 2016-04-06 | 2020-07-10 | Molecules Gm Innovative | Aminothiazole derivatives useful as antiviral agents |
| JP6978501B2 (ja) * | 2016-11-28 | 2021-12-08 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Ｎ−［５−（アミノスルホニル）−４−メチル−１，３−チアゾール−２−イル］−ｎ−メチル−２−［４−（２−ピリジニル）−フェニル］−アセトアミド遊離塩基半水和物、製造方法およびその用途 |
| UY37498A (es) | 2016-11-28 | 2018-06-29 | Aicuris Anti Infective Cures Gmbh | Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-20 metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la misma |
| WO2018095576A1 (en) * | 2016-11-28 | 2018-05-31 | Aicuris Anti-Infective Cures Gmbh | Topical pharmaceutical formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide |
| KR102335327B1 (ko) | 2017-04-28 | 2021-12-03 | 현대자동차 주식회사 | 수냉식 이지알 쿨러 |
| CN110831577B (zh) * | 2017-06-28 | 2023-11-28 | 艾库里斯有限及两合公司 | 包含抗病毒化合物的阴道内施用型装置 |
| KR102708082B1 (ko) | 2017-10-05 | 2024-09-19 | 이노베이티브 몰리큘스 게엠베하 | 항바이러스 화합물로서 치환된 티아졸의 거울상 이성질체 |
| US11964969B2 (en) | 2018-07-06 | 2024-04-23 | Phaeno Therapeutics Co., Ltd | Crystal forms of thiazole compound and application thereof |
| US12383508B2 (en) * | 2018-09-19 | 2025-08-12 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| CA3168721A1 (en) * | 2020-03-26 | 2021-09-30 | Jessica Redmer | Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate |
| EP4581031A1 (en) | 2022-08-29 | 2025-07-09 | Assembly Biosciences, Inc. | A novel crystalline form of pritelivir |
| CA3265860A1 (en) | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | Pharmaceutical compositions against the herpes virus |
| WO2024047506A1 (en) | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | A novel crystalline form of pritelivir |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2000000109A (es) | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| DE10129716A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Kombinationspräparate zur Herpes-Behandlung |
| DE10129714A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Topische Anwendung von Thiazolylamiden |
| DE10129717A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Kombinationspräparate zur Herpes-Behandlung |
| DE10131128A1 (de) * | 2001-06-28 | 2003-01-16 | Bayer Ag | Sekundäre Sulfonamide |
| GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| DE102005014248A1 (de) | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
| JP2007314516A (ja) * | 2006-04-25 | 2007-12-06 | Daiichi Sankyo Co Ltd | ２以上の置換基を有するベンゼン化合物を含有する医薬 |
| MX2008015638A (es) * | 2006-06-09 | 2009-01-09 | Icos Corp | Acidos fenil aceticos sustituidos como antagonistas de dp-2. |
| AR070127A1 (es) * | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
| UA103918C2 (en) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| EP2573085A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| EP2573086A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
-
2011
- 2011-09-26 EP EP11007823A patent/EP2573086A1/en not_active Withdrawn
-
2012
- 2012-09-21 TW TW105109173A patent/TWI567070B/zh active
- 2012-09-21 TW TW101134784A patent/TWI532739B/zh active
- 2012-09-23 JO JOP/2012/0276A patent/JO3037B1/ar active
- 2012-09-26 DK DK12762300.7T patent/DK2598501T3/da active
- 2012-09-26 PL PL13157396T patent/PL2602258T3/pl unknown
- 2012-09-26 ES ES13157396.6T patent/ES2466221T3/es active Active
- 2012-09-26 IN IN1993DEN2014 patent/IN2014DN01993A/en unknown
- 2012-09-26 MX MX2015016192A patent/MX371088B/es unknown
- 2012-09-26 MY MYPI2017702805A patent/MY190878A/en unknown
- 2012-09-26 ES ES12762300.7T patent/ES2462492T3/es active Active
- 2012-09-26 PL PL12762300T patent/PL2598501T3/pl unknown
- 2012-09-26 RU RU2014107430A patent/RU2620604C2/ru active
- 2012-09-26 DK DK13157396.6T patent/DK2602258T3/da active
- 2012-09-26 HR HRP20140351AT patent/HRP20140351T1/hr unknown
- 2012-09-26 UA UAA201404411A patent/UA115317C2/uk unknown
- 2012-09-26 PH PH1/2014/500567A patent/PH12014500567A1/en unknown
- 2012-09-26 US US14/347,287 patent/US9340535B2/en active Active
- 2012-09-26 RU RU2017114501A patent/RU2669388C1/ru active
- 2012-09-26 MX MX2014003389A patent/MX338736B/es active IP Right Grant
- 2012-09-26 EP EP12762300.7A patent/EP2598501B1/en active Active
- 2012-09-26 CA CA2791142A patent/CA2791142C/en active Active
- 2012-09-26 PE PE2014000390A patent/PE20141148A1/es active IP Right Grant
- 2012-09-26 KR KR1020177012548A patent/KR20170055565A/ko not_active Ceased
- 2012-09-26 MY MYPI2014000656A patent/MY185063A/en unknown
- 2012-09-26 CN CN201280046744.6A patent/CN103842359B/zh active Active
- 2012-09-26 AR ARP120103551A patent/AR088043A1/es not_active Application Discontinuation
- 2012-09-26 CN CN201511005819.8A patent/CN105541829A/zh active Pending
- 2012-09-26 KR KR1020147004026A patent/KR101768295B1/ko active Active
- 2012-09-26 KR KR1020187021891A patent/KR20180088530A/ko not_active Ceased
- 2012-09-26 UA UAA201704493A patent/UA119574C2/uk unknown
- 2012-09-26 JP JP2014532361A patent/JP6161614B2/ja active Active
- 2012-09-26 WO PCT/EP2012/068938 patent/WO2013045479A1/en not_active Ceased
- 2012-09-26 SG SG10201407430TA patent/SG10201407430TA/en unknown
- 2012-09-26 AU AU2012314536A patent/AU2012314536B2/en active Active
- 2012-09-26 BR BR112014003245-9A patent/BR112014003245B1/pt active IP Right Grant
- 2012-09-26 EP EP13157396.6A patent/EP2602258B8/en active Active
- 2012-09-26 PT PT127623007T patent/PT2598501E/pt unknown
- 2012-09-26 KR KR1020197025387A patent/KR20190104249A/ko not_active Ceased
-
2013
- 2013-12-24 IL IL230152A patent/IL230152A/en active IP Right Grant
-
2014
- 2014-01-20 CL CL2014000149A patent/CL2014000149A1/es unknown
- 2014-03-11 ZA ZA2014/01773A patent/ZA201401773B/en unknown
- 2014-09-01 IL IL234405A patent/IL234405A/en active IP Right Grant
- 2014-09-02 HK HK16109165.2A patent/HK1220978A1/zh unknown
- 2014-11-27 ZA ZA2014/08734A patent/ZA201408734B/en unknown
-
2015
- 2015-11-24 AU AU2015260762A patent/AU2015260762B2/en active Active
- 2015-12-16 PH PH12015502801A patent/PH12015502801B1/en unknown
-
2016
- 2016-06-07 JO JOP/2016/0114A patent/JO3734B1/ar active
- 2016-12-22 JP JP2016249351A patent/JP6353022B2/ja active Active
-
2019
- 2019-09-13 AR ARP190102595A patent/AR116394A2/es not_active Application Discontinuation
-
2020
- 2020-10-23 AR ARP200102938A patent/AR120291A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1220978A1 (zh) | N-[5-(氨基磺酰基)-4-甲基-1，3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物 | |
| AU2012314473B2 (en) | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations. | |
| HK1196018B (en) | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate | |
| HK1196018A (en) | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate | |
| CA2939529C (en) | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate | |
| NZ621615B2 (en) | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate | |
| NZ718867B2 (en) | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate | |
| EP2598502A1 (en) | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations. |